fda approves generic glp 1 Article » ProAct FDA Ban on Compounded GLP-1
Description
OTC GLP-1 boosters are marketed for weight loss, but pharmacists should help patients distinguish evidence-based care from supplement claims.
Results We identified 196,691 individuals with type 1 diabetes, 13% of whom were treated with adjunctive glucose-lowering therapy in addition to insulin
In the 2026 survey 73.9% (249/337 [95% CIs 69.0-78.4%]) of patients who are eligible for a GLP-1RA who have not used these a GLP-1RA and have expressed an interest in participating in a clinical trial of a GLP-1RA
Some studies showed equivalentor even lowertotal weight loss at one year compared to surgery alone
